Aggressive lymphoma

HMP Global announces International Myeloma Foundation (IMF) as partner with Lymphoma, Leukemia & Myeloma Congress (LL&M)

Retrieved on: 
Tuesday, July 18, 2023
Lymphoma, Learning, Translational Genomics Research Institute, Partnership, Sheraton New York Times Square Hotel, Aggressive lymphoma, Education, International Myeloma Foundation, Drug discovery, Multiple myeloma, Pathology, Bone marrow, Hematology, Research, LL, Science, Congress, Pharmacist, City, Patient, Practitioner, Physician, Weill Cornell Medicine, Biology, Faculty, Rare, Health, City of Hope National Medical Center, Leukemia, IMF, Pharmaceutical industry, Nursing, MD

MALVERN, Pa., July 18, 2023 /PRNewswire-PRWeb/ -- HMP Global, the leading omnichannel healthcare events and education company, today announced the International Myeloma Foundation (IMF) as a partner for the 2023 Lymphoma, Leukemia & Myeloma Congress (LL&M), the premier forum for industry-leading hematologic research and clinical case studies.

Key Points: 
  • MALVERN, Pa., July 18, 2023 /PRNewswire-PRWeb/ -- HMP Global, the leading omnichannel healthcare events and education company, today announced the International Myeloma Foundation (IMF) as a partner for the 2023 Lymphoma, Leukemia & Myeloma Congress (LL&M), the premier forum for industry-leading hematologic research and clinical case studies.
  • The 2023 LL&M Congress will be held October 18-21 at the Sheraton New York Times Square Hotel in New York City.
  • The educational program covers emerging data, innovative treatment methods, and emerging trends in lymphoma, myeloma, and leukemia disorders.
  • The International Myeloma Foundation is the first and largest global organization that focuses specifically on multiple myeloma, with more than 525,000 members in 140 countries.

FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Retrieved on: 
Friday, June 16, 2023
Research, FDA, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, DSM-IV codes, Rituximab, The New England Journal of Medicine, Polatuzumab vedotin, GemOx, Follicular lymphoma, Solar cycle 1, CRS, DLBCL, Oxaliplatin, OR, Lenalidomide, Aes, Cancer, Advanced Therapy Medicinal Product, B-cell lymphoma, Rash, ROG, RO, Aggressive lymphoma, CAR, HIV disease progression rates, Cytokine release syndrome, Patient, Risk, CR, European Medicines Agency, Phase, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Fatigue, Roche, Pharmaceutical industry, Genentech, Mosunetuzumab

This indication is approved under accelerated approval based on response rate and durability of response in the Phase I/II NP30179 study.

Key Points: 
  • This indication is approved under accelerated approval based on response rate and durability of response in the Phase I/II NP30179 study.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • While many people with DLBCL are responsive to treatment, the majority of those who relapse or are refractory to subsequent treatments have poor outcomes.
  • Columvi is the first and only CD20xCD3 T-cell engaging bispecific antibody for the treatment of R/R DLBCL that is given for a defined period of time.

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma

Retrieved on: 
Tuesday, June 6, 2023
CD19, Lymphoma, Cell, Aggressive lymphoma, CAR, Patient, SAN, MD Anderson Cancer Center, Therapy, ROR1, Pharmaceutical industry

“We are excited to announce the first patient, who had failed previous CD19 CAR T therapy, has been treated with ONCT-808,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.

Key Points: 
  • “We are excited to announce the first patient, who had failed previous CD19 CAR T therapy, has been treated with ONCT-808,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.
  • “We believe ONCT-808 has the potential to produce robust and durable responses for patients suffering from aggressive lymphoma.
  • Preclinical models show robust and specific activity against ROR1 expressing cells from multiple tumor types.
  • Oncternal has developed a manufacturing process that is reproducible, scalable, and only 8 days in duration.

Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies

Retrieved on: 
Tuesday, May 2, 2023
Janssen Pharmaceuticals, Antigen, CD19, Hematology, CD20, Lymphoid leukemia, Commitment, Food and Drug Administration, NHL, Janssen, Research, B-cell lymphoma, Science, Aggressive lymphoma, Delivery, Regenerative medicine, CAR, Development, Investigational New Drug, Lymphoma, Patient, Hart–Scott–Rodino Antitrust Improvements Act, Growth, Johnson & Johnson, EPS, FDA, IND, Food, Pharmaceutical industry, DLBCL

HORSHAM, Pa., May 2, 2023 /PRNewswire/ -- Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. These investigational CD20-directed autologous CAR-Ts have demonstrated promising overall and complete response rates in Phase 1 studies in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) in China, with the majority of study participants having diffuse large B-cell lymphoma (DLBCL), the most common type of aggressive lymphoma accounting for approximately one-third of B-cell lymphomas globally.1,2

Key Points: 
  • A Phase 1b study in the U.S. evaluating C-CAR039 in the treatment of patients with R/R DLBCL is underway.
  • Under terms of the agreement, CBMG will grant Janssen a worldwide license to develop and commercialize the CAR-T assets, except in Greater China.
  • Janssen and CBMG will negotiate an option for Janssen to commercialize the products in the China territory.
  • "The Cellular Biomedicine Group team has discovered differentiated cell therapies with clinically validated CD20 CAR constructs, and we look forward to harnessing our expertise, capabilities and scale to lead the global development of these innovative CAR-T products."

Richter's Syndrome Market Research Report 2023: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecasts, 2017-2022 & 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 26, 2023
Health, Other Health, Lymphoma, Lymphocytosis, Radiation, Prevalence, Chronic lymphocytic leukemia, Epidemiology, Bone marrow, Haematopoietic system, Richter's transformation, PET-CT, Consultant, Aggressive lymphoma, CAR, Patient, Investment, Engineering, Flow cytometry, Diagnosis, Safety, Pharmaceutical industry, Medical imaging, Vaccine, Growth

The "Richter's Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Richter's Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The Richter's syndrome market size in top seven countries reached US$ 430.5 Million in 2022.
  • Looking forward, the market in the top seven countries to reach US$ 685.7 Million by 2032, exhibiting a CAGR of 4.32% during 2022-2033.
  • The rising prevalence of aggressive lymphoma in individuals with chronic lymphocytic leukemia and small lymphocytic lymphoma is primarily driving the Richter's syndrome market.

Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025

Retrieved on: 
Monday, April 3, 2023
CLL, ROR1, Aggressive lymphoma, CD19, TP53, Clinical trial, Lung cancer, Cell, N, BTK, PFS, CAR, Patient, Investment, SAN, Bone marrow, MCL, Therapy, IND, LBD, AR, Safety, Prostate cancer, Pharmaceutical industry

The Phase 3 study and the Phase 1/2 study of zilovertamab in combination with ibrutinib will be closed, and other project and indirect expenses will be reduced, resulting in extending the expected cash runway into 2025.

Key Points: 
  • The Phase 3 study and the Phase 1/2 study of zilovertamab in combination with ibrutinib will be closed, and other project and indirect expenses will be reduced, resulting in extending the expected cash runway into 2025.
  • The projected cash runway will support the clinical advancement of our two pipeline assets ONCT-808 and ONCT-534.
  • “The dramatic adoption of recently approved Bruton’s tyrosine kinase inhibitors made the continued development of zilovertamab with ibrutinib an unviable commercial opportunity.
  • We estimate that our cash, cash equivalents and short-term investments were $54.3 million, and we had 58.7 million shares of common stock outstanding, as of March 31, 2023, and we expect our cash, cash equivalents and short-term investments to support our planned operations into 2025.

FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma

Retrieved on: 
Friday, January 6, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, The New England Journal of Medicine, Cancer, Hoffmann-La Roche, Priority review, Food, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Oxaliplatin, BLA, Lymphatic system, OR, Royal commission, Mantle cell lymphoma, DLBCL, NHL, HIV disease progression rates, Aggressive lymphoma, CAR, CRS, Patient, Cytokine release syndrome, ROG, RO, European Commission, FDA, Rituximab, Lymphoma, B-cell lymphoma, Phase, GemOx, Hematology, Incidence, Society, CR, Pharmaceutical industry, Genentech

The FDA is expected to make a decision on approval of this novel cancer immunotherapy by July 1, 2023.

Key Points: 
  • The FDA is expected to make a decision on approval of this novel cancer immunotherapy by July 1, 2023.
  • If approved, glofitamab would be the first fixed-duration, off-the-shelf CD20xCD3 T-cell engaging bispecific antibody available to treat people with an aggressive lymphoma who have previously received multiple courses of treatment.
  • The FDA will review the glofitamab BLA under the granted Fast Track Designation.
  • Glofitamab is part of Genentech’s industry-leading CD20xCD3 T-cell engaging bispecific antibody clinical program, which is the broadest and most advanced in lymphoma.

Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cytokine, CD3, Society, NHL, Cancer, Anemia, B-cell lymphoma, Safety, AE, Lymphoma, Patient, IL-6, COVID-19, DLBCL, Form 10-K, Cytokine release syndrome, Lymphocytopenia, Trial of the century, Clinical trial, Annual report, CST, Security (finance), Probability, III, Neutropenia, Non-Hodgkin lymphoma, Aggressive lymphoma, CD20, CD28, ITT, ASH, Therapy, ORR, Lenalidomide, CR, Follicular lymphoma, Degenerative disease, Incidence, Histology, Antibody, Engineering, CRS, AES, Janssen, Vaccine, Pharmaceutical industry, Cmax

In the Phase 1 monotherapy study of plamotamab, the recommended intravenous dose was well tolerated, and we are encouraged by the responses observed in the study.

Key Points: 
  • In the Phase 1 monotherapy study of plamotamab, the recommended intravenous dose was well tolerated, and we are encouraged by the responses observed in the study.
  • Xencors first combination study, evaluating plamotamab with tafasitamab plus lenalidomide, is enrolling patients with advanced, aggressive lymphoma.
  • Additionally, patients enrolling to the ongoing Phase 1 monotherapy study will now receive subcutaneous doses of plamotamab.
  • Plamotamab is also being evaluated in a Phase 2 study, in combination with tafasitamab plus lenalidomide, in patients with relapsed or refractory diffuse large B-cell lymphoma.

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma

Retrieved on: 
Thursday, September 15, 2022
Adult, Lymph, Risk, STAT3, Therapy, Peripheral T-cell lymphoma not otherwise specified, Safety, COVID-19, Twitter, PTCL, FDA, CTCL, Entrepreneurship, Food, Lymphatic system, Blood, Skin, Peripheral, LinkedIn, Itch, Cutaneous T cell lymphoma, Degenerative disease, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, T-cell lymphoma, CEO, Annual report, Nasdaq, Diagnosis, Science, Boston Business Journal, NASDAQ, Aggressive lymphoma, Boston, Security (finance), Biotechnology, Rash, GLOBE, Medicine, Cancer, Lymphoma, Peripheral T-cell lymphoma, Pharmaceutical industry, Black Majesty

Deregulation of STAT3 signaling has been implicated in the pathogenesis of a variety of cancers, including CTCL.

Key Points: 
  • Deregulation of STAT3 signaling has been implicated in the pathogenesis of a variety of cancers, including CTCL.
  • KT-333 received orphan drug designation for the treatment of Peripheral T-cell Lymphoma ( PTCL ) earlier this year.
  • TheFDA'sOrphan Drug Designation program provides orphan status to drugs defined as those intended for the treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people inthe United States.
  • Orphan drug designation qualifies the sponsor of the drug for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon FDA approval.

Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, August 11, 2022
IPSC, U.S. Securities and Exchange Commission, D.C, Risk, Russell Microcap Index, CD19, GLOBE, R, Investment, Clinical trial, Cancer, Security (finance), Marketing, Patient, Ink, Research and development, Poster, Glioblastoma, American Society of Gene and Cell Therapy, Food, Indolent lymphoma, Annual general meeting, B cell, Aggressive lymphoma, Gene, Century, Investigational New Drug, Intellectual property, Bristol Myers Squibb, BMS, Therapy, COVID-19, Program, Glossary, Maintenance, Food and Drug Administration, Genetic engineering, FDA, Cell, Private Securities Litigation Reform Act, Common, CGMP, NK, IND, Society, Company, NASDAQ, CRISPR, GAAP, Research, Administration, Adult, Information technology, Pharmaceutical industry, Life insurance, Development

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc., (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the second quarter ended June 30, 2022.

Key Points: 
  • Additionally, we look forward to providing updates on our gamma delta iT platform and other program advancements in the coming months.
  • Century expects to submit an Investigational New Drug (IND) application for CNTY-103 in 2024.
  • Century was added to the Russell Microcap Index in June 2022.
  • We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations.